Search page

A Regulatory Risk haplotype in HLA-DQ region regulates antigen presentation of monocyte in Type 2 inflammation in chronic rhinosinusitis with nasal polyps

ANCHOR-1 and 2 Study Design: Replicate Phase 3 Randomised, Double-Blind, Placebo-Controlled Studies of the Efficacy and Safety of Depemokimab in Patients with Chronic Rhinosinusitis with Nasal Polyps

Aerobiology and pollution 2

Allergen immunotherapy 2

Allergy diagnosis 2

Allergy to Red Mullet and Seabass: 2 Newly Identified Allergens

Anaphylaxis 2

Artificial intelligence-based B-cell epitope peptide immunotherapy alleviates chitin-binding protein-induced type 2 airway inflammation in Blomia tropicalis

Assessing the Impact of Dupilumab Treatment on Lung Function in Patients With Chronic Obstructive Pulmonary Disease and Type 2 Inflammation

Asthma 2

Barzolvolimab Significantly Improves Angioedema in Patients with Chronic Spontaneous Urticaria (CSU): Results from a Phase 2 Trial

Basic immunology 2

Benefits of the combination of biologics in the control of a patient with high type 2 profile: a case report

Biologicals 2

Biologics have Solved the Problem of Type 2 Asthma

Biomarkers 2

COVID19 2

Cannabinoid agonist WIN55,212-2 improves bronchial epithelial barrier alterations in the context of viral infection and type 2 inflammation

Characteristics of Severe type 2 Asthma Patients in China: A Retrospective Observational Study

Characterization of chronic rhinosinusitis patients based on markers of type 2 inflammation: Findings from the European CRS Outcome Registry (CHRINOSOR)

Comparative phase 2 bioavailability study of a fast acting, dry powder-based, epinephrine intra-nasal formulation, FMXIN002, for anaphylaxis

Concordance of Immunoblot, Alex 2 and Skin Prick Test in the detection of respiratory allergens in patients with allergic rhinitis in a private center of Arequipa – Perú

Cysteine Protease Fic c 2 in Fig-Induced Allergy: A Case Study on Cross-Reactivity

Cytometric detection of Der p 1 and Der p 2 binding to Basophils (CytoBas) enables precise determination of house dust mite sensitization in patients with asthma and allergic rhinitis

Dermatology 2

Desensitization Protocol for Cemiplimab Immediate Hypersensitivity Reactions due to Cytokine Release in Lung Cancer: Report of 2 cases

Designing Modified Variants of Ara h 1 and Ara h 2 for Safe and Effective Immunotherapy

Dietary fructo-oligosaccharides induced suppression of type 2 inflammation coincides with changes in the fecal microbiome and local and systemic short chain fatty acids levels in a mouse model for house-dust-mite allergy

Dietary intervention with fructo-oligosaccharides in a mouse-model for house dust mite allergy enhances type 1, while lowering HDM specific type 2 responses in the lungs

Dissecting the molecular mechanisms underlying TSLP-driven non-type 2 inflammatory responses in severe asthma

Distribution of Baseline Type 2 Inflammation Characteristics in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Biologic Clinical Trials: A Comparative Assessment

Drug allergy 2

Dupilumab Improves Lung Function and Reduces Exacerbation Frequency and IgE Levels in Patients with Asthma and Allergic Bronchopulmonary Aspergillosis (Phase 2 LIBERTY ABPA AIRED Study)

Dupilumab Improves Type 2 Inflammatory Biomarkers Over Time in Patients With Chronic Obstructive Pulmonary Disease

Dupilumab Reduces Exacerbations and Improves Asthma Control in Children With Moderate-to-Severe Type 2 Asthma, Regardless of Asthma Duration

Dupilumab Reduces FeNO levels and Exacerbations and Improves Asthma Control with Inhaled Corticosteroid Withdrawal: a Phase 2 Study

Dupilumab Reduces Seasonal Exacerbation Rates in Children With Type 2 Asthma With or Without Evidence of Allergy

Dupilumab Treatment Reduces IgE Levels in Patients Aged 2 to 17 Years With Atopic Dermatitis, Asthma, and Eosinophilic Esophagitis

Dupilumab Treatment is Associated with Clinical Improvement and a Shift towards a health-associated Nasal Passage Microbiota in Diffuse Type 2 Chronic Rhinosinusitis

Dupilumab treatment effectively reduces nasal type 2 cytokine production following acetylsalicylic acid provocation in N-ERD patients

Dupilumab-induced eosinophilia in patients with diffuse type 2 chronic rhinosinusitis

EAACI Enlightening Talks – 2

ENT 2

EUROBAT Symposium 2 – Guidelines, position papers and consensus protocols for BAT

Effects of dupilumab on quality of life and airflow obstruction in refractory type 2 high severe unified airways disease

Efficacy and Safety of Dupilumab in Children Aged 6 Months to 5 Years With Atopic Dermatitis With and Without Type 2 Comorbidities

Efficacy and Safety of Oral Deucrictibant, a Potent Bradykinin B2 Receptor Antagonist, in Prophylaxis of Hereditary Angioedema Attacks: Results of CHAPTER-1 Phase 2 Trial

Efficacy of Rilzabrutinib on Asthma Control: Results From a Double-Blind Placebo-Controlled Phase 2 Study

Efficacy of Rilzabrutinib on Asthma Quality of Life: Results From a Double-Blind Placebo-Controlled Phase 2 Study

Eosinophil-derived neurotoxin measured in nasal mucosal lining fluid (Nasosorption) is a promising type 2 biomarker in allergic rhinitis

Eosinophilic Esophagitis and Atopy: A Shared Mechanism of Type 2 Inflammation

Epidemiology 2

Evaluating the Effect of Dupilumab on Type 2 Airway Inflammation and Mucus Plugging in Patients With Uncontrolled Moderate-to-Severe Asthma: The VESTIGE Trial

Expansion of allergen-specific type 2 memory B cells with an altered phenotype after immunotherapy for bee venom or ryegrass pollen allergy

Flash Talk 2

Flash talks on Allergen Immunotherapy 2

Flash talks on Allergy Diagnosis 2

Flash talks on Drug Allergy 2

Flash talks on Food Allergy 2

Food allergy 2

Ground breaking discoveries 2

Hereditary α-Tryptasemia in Severe Allergic Asthma: Impaired Lung Function, Reduced Type 2 Biomarkers, and Suboptimal Omalizumab Response

High level summit on Primary Immunodeficiencies – Session 2

Home egg ladder initiation in egg allergic infants: 2 year follow-up

How can we unravel the type 2 low mechanism

IL-10-producing group 2 innate lymphoid cells

Identification of candidate biomarkers for diagnosing and assessing the disease severity of type 2 hereditary angioedema via plasma N-glycomics

Immune deficiencies and autoimmunity 2

Immunostimulatory or immunosuppressive role of type 2 innate lymphoid cells

Improvement in Lung Function with Rademikibart in Eosinophilic Driven, Type 2 Asthma

Increase in airway resistance and respiratory bronchial reactivity is accompanied by cellular and antibody Type 2 immune response in a mouse model of asthma induced by Der p 23 allergen

Indirect case matched comparison of dupilumab versus benralizumab on mannitol airway hyperresponsiveness in type 2 high severe asthma

Interim safety review of PVX108 peptide immunotherapy in an ongoing Phase 2 trial in peanut-allergic adolescents and children

Involvement of Janus kinase (JAK)-dependent Bcl-xL overexpression in steroid resistance of group 2 innate lymphoid cells (ILC2s) in asthma

LPS presence promotes, but is not required for, an ovalbumin induced type 2 mucosal immune response in vitro

Long-Term Analysis of the Phase 2 Open-Label Extension of Donidalorsen in Patients With Hereditary Angioedema

Lung Function Improvement is Associated With Better Asthma Control in Adolescents and Adults Aged 12 Years and Older With Moderate-to-Severe Type 2 Asthma: A Post Hoc Analysis of QUEST

Lung Function Responder Rates in the VOYAGE study in Children with Moderate-to-Severe Type 2 Asthma Receiving Dupilumab at Week 52

Lung function and exacerbations by different type 2 inflammation criteria in a general asthma population

Managing patients with Type 2 inflammation in a joint interdisciplinary “United Airways Clinic” at Lund University Hospital, Sweden

Mepolizumab Improves and Sustains Asthma Control and Lung Function in Patients with Severe Asthma Independent of Baseline Blood Eosinophil Count in the Real World: Results from REALITI-A at 2 Years

Methyl-CpG binding protein 2 (MECP2) gene mutation associated with a T-cell immunodeficiency

Mini Masterclass – Successfully managing transition of adolescents into the adult – Session 2

Modulation of allergen-specific type 2 memory B cells over the course of 18 months sublingual immunotherapy for house dust mite allergy

Murine IgG1 corresponding to human IgG4 increased by subcutaneous immunotherapy suppressed activation of group 2 innate lymphoid cells

NAS Talks – 2

Novel IgE molecular diagnosis Alex 2 in Uruguay (Latin america)

Novel roles of type 2 innate lymphoid cells in allergic diseases

Occupational allergy 2

Oral Abstract Session 2 – Atopic Dermatitis

Outcomes in chronic rhinosinusitis and type 2 inflammation

PDS3: Food Allergy Management 2

Pediatrics 2

Phase 2 Study to Evaluate the Sensitivity, Specificity, and Safety of DBV1605 as a Diagnostic Tool for Non–IgE-Mediated Cow’s Milk Allergy in Children (APTITUDE)

Poster Session 2

Presentation test 2

Real-world change in asthma symptom control and oral corticosteroid use in patients with severe asthma treated with mepolizumab stratified by atopic status: Post hoc analysis of REALITI-A at 2 years

Real-world effectiveness of dupilumab in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) is independent of comorbidities, sinus surgery history and level of type 2 inflammation: Findings from CHRINOSOR

Recombinant expression of genetically modified Ara h 2 in Komagataella phaffii

Reduction in Annualized Exacerbations with Rademikibart in Eosinophilic Driven, Type 2 Asthma

Reduction in Weekly Urticaria Activity Score (UAS7) With Rilzabrutinib in Patients With Chronic Spontaneous Urticaria: 12-Week Results From the RILECSU Phase 2 Dose-Ranging Study

Registry on Severe Asthma with and without biological treatment in Spain: Results of a 2 year follow-up of AlergoDATA

Regulation of the type 2 imprint by microbes and environmental factors

Rilzabrutinib Results in Rapid Improvement of Symptoms in Patients With Chronic Spontaneous Urticaria: Results From the RILECSU Phase 2 Dose-Ranging Study

SLC27A2 marks lipid peroxidation in nasal epithelial cells driven by type 2 inflammation in chronic rhinosinusitis with nasal polyps

Scientific Symposium 2

Skin prick tests with Der p 1, Der p 2 and Der p 23: are they useful?

Small group session 2 – Improving self-management

Structural analysis of IgE epitopes of Ara h 2 reveals simultaneous binding of three copies of a human derived IgE Fab fragment to the major peanut allergen

Structural analysis of IgE epitopes on major peanut allergens Ara h 2 and Ara h 6

Systematic literature review and adjusted indirect treatment comparisons of 2 allergen immunotherapy treatments for grass pollen–induced allergic rhinitis

The Importance of Differential Diagnosis in DRESS Syndrome: Review of 2 Cases

The Influence of Dupilumab on the Nasal and Gastrointestinal Microbiome in Diffuse Type 2 Chronic Rhinosinusitis

The effect of therapies targeting Type 2 inflammation on Neutrophil Extracellular Traps (NETs) and Extracellular Eosinophilic Traps (EETs) in severe CRSwNP

The m6A demethylase FTO mediates type 2 inflammation in asthma by regulating STAT6 mRNA stability

The role of sirtuin 2 (SIRT2) in atopic dermatitis

The triple type 2 signature is associated to asthma severity and comorbidity with CRS

Tumor Necrosis Factor Receptor 2 (TNFR2) is crucial for the efficacy of Allergen-Specific Immunotherapy in a Pre-clinical Murine Model

Type 2 Responses and the Future of Food Allergy Treatment: A Biological Perspective

Type 2 immunity at the mucosal barriers

Type 2 innate lymphoid cells in cancer immunity.

Type 2 responses in the lungs: mechanisms and implications

YEAR-IN-REVIEW 2

YIR 2

Year in Review 2

Dupilumab: Real-Life Effectiveness, Safety, and Impact on Type 2 and Non-Type 2 Comorbidities in Atopic Dermatitis Across Paediatric, Adolescent, and Adult Patients in Argentina – A 5-Year Review

Welcome

Only match titles

What are you looking for?

Knowledge Hub

Website

Only match titles

What are you looking for?

Knowledge Hub

Sponsored Symposia

Event Resources

Covid-19

Courses

Website

Sessions

Annual Congress